MedTrace Logo

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

NCT02983214 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 826

Last updated 2020-12-29

No results posted yet for this study

Summary

Investigation of the clinical efficacy and safety of dual antiplatelet therapy with clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in patients with type 2 diabetes and symptomatic peripheral arterial disease.

Conditions

Interventions

DRUG

Clopidogrel

DRUG

Cilostazol

Sponsors & Collaborators

  • LIBYTEC Pharmaceutical S.A.

    collaborator UNKNOWN

  • University of Ioannina

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983214 on ClinicalTrials.gov